Pluri has expanded its 2024 manufacturing agreement with Remedy Cell, confirming full technology transfer of Remedy Cell’s proprietary, cell-free secretome process into Pluri’s GMP facility and the successful production of multiple clinical-grade batches of the company’s lead candidate. The material is intended for an initial Phase 1b study in idiopathic pulmonary fibrosis, and the scope of the partnership now broadens to include additional manufacturing and process-development support as Remedy Cell advances toward clinical and pre-commercial stages.
The strategic question is whether specialized CDMOs will become the decisive gatekeepers for next-generation, cell-derived yet cell-free therapeutics. By moving beyond traditional cell therapy and into secretome-based biologics, both companies are betting that manufacturability and CMC credibility will differentiate winners from well-meaning science projects. In a market where first-in-human timelines increasingly hinge on GMP readiness and potency analytics, this tie-up underscores that development risk is shifting from lab bench to bioprocess rigor.
The timing matters. IPF remains an area of profound unmet need despite decades of work, with current standards slowing decline rather than regenerating function. Recent late-stage setbacks in fibrosis have sharpened payer scrutiny and raised the bar for differentiation. A secretome therapy—positioned as off-the-shelf, multi-target, and potentially pro-regenerative—offers an alluring narrative, but it will be judged on hard data: impact on FVC slope, exacerbations, hospitalizations, and additive benefit on top of nintedanib or pirfenidone. If early signals emerge, Medical Affairs teams will need to equip pulmonologists with pragmatic guidance on patient selection, background therapy management, and biomarker interpretation, from serum fibrosis markers to imaging-based quantitation.
For Commercial leaders, the manufacturing angle is not a footnote. Secretome products are inherently heterogeneous, making release specifications, potency assays, and stability programs central to both regulatory acceptability and payer trust. A partner with a validated, automated 3D bioreactor platform and GMP track record can compress timelines, reduce capex, and improve comparability when scaling or modifying processes—key levers when facing global filings and post-approval change controls. If cost of goods can be constrained through scale and automation, pricing flexibility improves, which will matter in negotiations where payers will likely require robust comparative evidence or outcomes commitments given the history of inconclusive IPF trials.
This deal also reflects larger restructuring across biotech and advanced modalities. CDMOs with modality-specific expertise are absorbing more of the translational burden as small biotechs conserve cash and investors reward capital-light models. For competitors developing extracellular vesicle or other cell-derived, cell-free platforms, the message is clear: credible CMC narratives and early alignment on regulatory classification and potency will be as determinative as mechanism. Companies clinging to bespoke, in-house GMP for complex biologics may find themselves disadvantaged on speed, reliability, and eventually on price.
The next proof point will be clinical execution. If the Phase 1b program delivers safety, a consistent pharmacodynamic fingerprint, and a directional effect on lung function or exacerbations, the conversation shifts from plausibility to positioning. The bigger industry question follows: can secretome-based therapies convert their manufacturing and logistical advantages into demonstrable, disease-modifying impact—and will that be enough to clear rising payer evidentiary thresholds in fibrotic disease?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
